Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

Return to program book search

Session Information

SYM S008 - Common Controversies in Dermatologic Drug Therapy

Open admission, no tuition or ticket.


Date: Friday, August 17

CME Credits: 3.00

Location: Room 302

Time: 2:00 PM - 5:00 PM

Director: Stephen E. Wolverton, MD, FAAD


  • Kenneth B. Gordon, MD, FAAD
  • Julie Claire Harper, MD, FAAD
  • Theodore Rosen, MD, FAAD

Learning Objectives:
Following this course, the attendee should be able to:

  • Make informed decisions concerning common controversies in dermatologic drug therapy.
  • Evaluate controversies in future practice determining the pros, cons, and rationale for the most optimal clinical decisions.

This session is directed at clinicians who understand the need to be decisive with therapeutic controversies, even when data to make these decisions are not always complete. The triad of (1) literature support, (2) personal experience, and (3) biologic plausibility will guide decisions on various controversies. Topics discussed will include challenging decisions with antibacterials, hormonal contraceptives, isotretinoin, and various biologic therapeutic agents. Particular emphasis will be placed on the most worrisome potential adverse effects such as thromboembolism, carcinogenicity, opportunistic infections, and bacterial resistance.


Friday, August 17
2:00 PMCurrent controversies concerning antimicrobial resistance / Dr. Rosen
2:45 PMControversies concerning isotretinoin (IBD, depression) and hormonal contraceptives / Dr. Harper
3:30 PMDifficult decisions and concerns with biologic therapeutic agents / Dr. Gordon
4:15 PMBrand new controversies involving drug safety, including medicolegal concerns / Dr. Wolverton